The Ebola vaccine projects – EBOVAC1, EBOVAC2, EBODAC and EBOMAN – are a series of trials and associated projects which aim to assess a novel two-dose preventive vaccine regimen against Ebola Virus Disease (EVD). In a two-dose vaccine regimen, individuals are given a first dose to prime the immune system, and then a second dose which is intended to enhance the immune response and increase the duration of the response.
Between them the EBOVAC1 and EBOVAC2 projects are assessing – through several clinical trials conducted in phases in Europe and Africa – the safety, tolerability and immunogenicity of the vaccine regimen in response to the public health need raised by the West African Ebola epidemic of 2014-2016.
To expedite the development of the vaccine regimen, some stages of the trials are being carried out in parallel and are therefore being coordinated by two separate teams within the EBOVAC1 and EBOVAC2 projects.
Find out more about the trials:
EBOVAC1 and EBOVAC2 are working closely with the EBODAC vaccine deployment, acceptance and compliance project, and the EBOMAN vaccine manufacture capability project.
Find out more about these projects:
EBODAC – Vaccine deployment, acceptance and compliance
EBOMAN – Vaccine manufacture capability
Ebola signs in Freetown, Sierra Leone (Credit: Dr D Watson-Jones)
The Ebola vaccine projects are part of the Innovative Medicines Initiative Ebola+ programme
